The use of VEGFR-TKIs monotherapy in the treatment of unresectable or advanced HCC in 1L setting

Episode 4 October 19, 2021 00:30:42
The use of VEGFR-TKIs monotherapy in the treatment of unresectable or advanced HCC in 1L setting
COR2ED Medical Education
The use of VEGFR-TKIs monotherapy in the treatment of unresectable or advanced HCC in 1L setting

Oct 19 2021 | 00:30:42

/

Show Notes

The use of VEGFR-TKIs monotherapy in the treatment of unresectable or advanced HCC in 1L setting: Who can benefit and guidance on implementation of dosing-strategies and pre-habilitation of patients for the prediction of efficacy and toxicities in clinical practice

Prof. Josep Llovet and Prof. Stephen L. Chan discuss a very interesting topic about the use of the VEGFR TKIs monotherapy in the treatment of unresectable or advanced HCC in the first-line setting. They will go into details about who can benefit from monotherapy and will share the current guidance on the implementation of the dosing strategies for the management of toxicity in the clinical practice. They discuss first line monotherapy with TKI (lenvatinib or sorafenib) for patients who are not suitable for the treatment with atezo-bev combination (around 20% of the patients) which is the current standard of care. They summarize the HCC patients who are not ideal for this I/O combination such as HCC patients with liver transplantation, high bleeding risk, impaired liver function or severe autoimmune disease. The experts discuss about which patients can benefit from TKI and provide a summary of efficacy data and safety profile from various pivotal clinical studies (including SHARP, REFLECT, IMbrave150) as well as real-world data. Dosing-strategies for VEGFR-TKIs and management of AEs are discussed as well as guideline recommendations. Finally, the experts discuss key developments over the next few years focusing on the new immunotherapy combinations approach that could become new standard of care.

Other Episodes

Episode 1

September 23, 2021 00:18:01
Episode Cover

Diagnosis and treatment of TRK fusion-positive GI cancers

In this podcast, NTRK CONNECT members Prof Frédérique Penault-Llorca (University of Clermont-Ferrand, France) and Prof Andrea Sartore-Bianchi (Niguarda Cancer Centre, Milan, Italy) provide both...

Listen

Episode 1

September 06, 2021 00:21:52
Episode Cover

Optimising VEGFR-TKIs (MKIs) in Differentiated Thyroid Cancer

Dr. Jaume Capdevila, a Medical Oncologist at Vall d’Hebron University Hospital in Barcelona, Spain, and Dr. Rachel van Leeuwaarde, an Endocrinologist from the University...

Listen

Episode 1

June 08, 2022 00:22:00
Episode Cover

Management of Skin Toxicity with Multikinase Inhibitors

COR2ED Medical Education: In this podcast, Beth Wittmer RN, Director of Care Management at Florida Cancer Specialists, USA and Prof. Hans Prenen, GI Medical...

Listen